Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies

摘要

Objective. Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESRI) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (Als). The purpose of this study was to evaluate the frequency and clinical relevance of ESRI genomic alterations in gynecologic malignancies.